Colorectal Cancer

The top 5 OncLive TV videos of the week cover insights in colorectal cancer, breast cancer, bladder cancer, and more

Shubham Pant, MD, MBBS, discusses data from the phase 3 BREAKWATER trial supporting upfront targeted therapy in BRAF V600E–mutant mCRC.

Kanwal P.S. Raghav, MD, MBBS, discusses a phase 2 study evaluating the MET-directed ADC Temab-A vs SOC active surveillance in postadjuvant, ctDNA-positive CRC.

The FDA approved a teclistamab combination in relapsed/refractory myeloma, Pylarify TruVu for PSMA-PET imaging in prostate cancer, and more.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in February 2026 spanning tumor types.

John L. Marshall, MD, and Christopher Lieu, MD, comment on the rising incidence of early-onset colorectal cancer (CRC) during CRC Awareness Month.

Shubham Pant, MD, MBBS, discusses the importance of early biomarker testing in mCRC to guide targeted therapy selection and ensure full clinical benefit.

The FDA has granted accelerated approval to zongertinib in HER2 TKD–mutated NSCLC, full approval to an encorafenib combination in BRAF V600E+ mCRC, and more.

February brought key GI cancer updates: FDA approvals in BRAF+ mCRC and pancreatic cancer, plus new fast track and orphan designations.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Encorafenib plus cetuximab and fluorouracil-based chemotherapy has received traditional FDA approval for BRAF V600E–mutant metastatic colorectal cancer.

The top 5 OncLive TV videos of the week cover insights in genitourinary cancers, hematologic malignancies, colorectal cancer, and sarcoma.

Topline data from cohort 3 of BREAKWATER showed improvements in key secondary end points of PFS and OS in previously treated, BRAF V600E–mutant mCRC.

Christopher Lieu, MD, expands on current treatment strategies and factors informing third-line sequencing decisions in mCRC.

The FDA granted priority review to Dato-DXd in triple-negative breast cancer, accepted an NDA for zanzalintinib plus atezolizumab in mCRC, and more.

With an additional 16.1 months of follow-up, the dual HER2-targeted, chemotherapy-free regimen maintained efficacy and safety in HER2-positive mCRC.

The FDA issued a reminder to increase awareness regarding updated capecitabine and 5-FU labels to highlight DPD deficiency risks.

Pelareorep has received FDA fast track designation in combination with SOC bevacizumab and FOLFIRI in the second line for KRAS-mutant MSS mCRC.

An NDA for zanzalintinib plus atezolizumab in pretreated metastatic colorectal cancer is under review by the FDA.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, myelodysplastic syndrome, breast cancer, colorectal cancer, and cervical cancer.

Kanwal P.S. Raghav, MBBS, MD, discusses standards for data interpretation in clinical trials involving ctDNA testing in CRC.

Kanwal P.S. Raghav, MBBS, MD, discusses the mechanism of action of telisotuzumab adizutecan in post-adjuvant ctDNA-positive CRC.

The FDA has approved the Guardant360 CDx as a companion diagnostic for encorafenib in patients with mCRC harboring BRAF V600E mutations.

Rocío García-Carbonero, MD, discusses the rationale of the FRESCO-2 trial of fruquintinib in mCRC.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, breast cancer, and colorectal cancer.